Griseofulvin
- Generic Name
- Griseofulvin
- Brand Names
- Gris-peg
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17ClO6
- CAS Number
- 126-07-8
- Unique Ingredient Identifier
- 32HRV3E3D5
- Background
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
- Indication
For the treatment of ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap or other conditions caused by Trichophyton or Microsporum fungi.
- Associated Conditions
- Tinea Capitis, Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Unguium, Tinea barbae
Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions
- Conditions
- Antifungal Agents
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT04318535
- Locations
- 🇮🇳
GSK Investigational Site, Navi Mumbai, India
Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 70
- Registration Number
- NCT01518166
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions
- Conditions
- Healthy
- Interventions
- Drug: Grifulvin V® 125 mg/5 mL Suspension, single dose
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00863863
- Locations
- 🇨🇦
Biovail Contract Research (A Division of Biovail Corporation), Toronto, Ontario, Canada
A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- Drug: Grifulvin V® 125 mg/5 mL Suspension, single dose
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00864071
- Locations
- 🇨🇦
Biovail Contract Research (A Division of Biovail Corporation), Toronto, Ontario, Canada
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
- Conditions
- Tinea Capitis
- Interventions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 720
- Registration Number
- NCT00117767
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.